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ABSTRACT
Objective To describe the development of the 
Nottingham liver disease stratification pathway, 
present a 12-month evaluation of uptake and 
stratification results, and compare the pathway 
with current British Society of Gastroenterology 
(BSG) guidelines.
Design A referral pathway between primary 
and secondary care for the detection and risk 
stratification of liver disease.
Setting Four Nottinghamshire clinical 
commissioning groups (700 000 population).
Patients Patients are referred to the pathway 
with (1) raised aspartate aminotransferase to 
alanine aminotransferase (AST:ALT) ratio, (2) 
harmful alcohol use or (3) risk or presence of 
non-alcoholic fatty liver disease (NAFLD).
Interventions We report on clinic attendance 
within secondary care for transient elastography 
(TE) and brief lifestyle intervention. The TE result 
is reported back to the general practitioner with 
advice on interpretation and referral guidance.
Main outcome measures Pathway uptake, 
patient characteristics, liver disease stratification 
results and stakeholder feedback.
Results Over the first 12 months 968 patients 
attended a TE clinic appointment, with raised 
AST:ALT ratio being the most common single 
reason for referral (36.9%). Of the total, 222 
(22.9%) patients had an elevated liver stiffness 
(≥8 kPa), in whom 57 (25.7%) had a liver stiffness 
which was indicative of advanced chronic liver 
disease. If a traditional approach based on raised 
liver enzymes (BSG guidance) had been followed, 
38.7% of those with significant liver disease 
(≥8 kPa) would have gone undetected among 
those referred for either NAFLD or raised AST:ALT 
ratio.
Conclusions Targeting patients with risk factors for 
chronic liver disease and stratifying them using TE 
can detect significant chronic liver disease above 
and beyond the approach based on liver enzyme 
elevation.
InTRoduCTIon
The need for early detection of liver 
disease in order to allow intervention and 
to change the course of the disease has 
been highlighted by three independent 
reports.1–3 With no nationally agreed 
assessment guidance, the approach used 
by general practitioners (GPs) to iden-
tify patients with chronic liver disease 
(CLD) varies widely. Current diagnostic 
pathways for the detection and onward 
referral of suspected CLD are based on 
raised liver enzymes, which lack accuracy 
and may result in delays to diagnosis.
Serum levels of alanine aminotrans-
ferase (ALT) have been used as an indi-
cator of liver cell injury for about 50 
years. It is however recognised that signif-
icant liver fibrosis exists in the context 
of normal ALT.4–6 Conversely, the prev-
alence of raised liver enzymes is high 
within general practice, and yield of liver 
disease diagnoses may be low.7 Latterly, 
several clinical scoring systems based 
on routine laboratory indices have been 
shown to identify advanced fibrosis in 
patients with liver disease. The aspartate 
aminotransferase to alanine aminotrans-
ferase (AST:ALT) ratio, BARD score and 
non-alcoholic fatty liver disease (NAFLD) 
fibrosis scores all have a high negative 
predictive value (>92%) for advanced 
fibrosis and as such can be used as tools 
to identify those most at risk of disease.8
Considering this, we developed a 
pathway to target the risk factors which 
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Figure 1 Nottingham liver disease stratification referral pathway. ALT, alanine aminotransferase; AST, aspartate aminotransferase; FLI, fatty liver 
index; MetS, metabolic syndrome; NAFLD, non-alcoholic fatty liver disease; T2DM, type 2 diabetes mellitus; USS, ultrasound.
underpin the two most common causes of liver disease 
in the UK, alcohol-related liver disease and NAFLD. 
The second conceptual change we made was to allow 
direct access to non-invasive tests of liver fibrosis 
within primary care. We chose transient elastography 
(TE), as this has been extensively validated against liver 
biopsy and gives an immediate test result permitting a 
prompt intervention with lifestyle advice.
Our first pilot study, performed in a suburban area 
of Nottingham, found 10% of patients had harmful 
alcohol or type 2 diabetes as risk factors for liver 
disease.9 Targeting these risk factors resulted in finding 
potentially significant liver disease (TE ≥8 kPa) in 
26.8% and cirrhosis (TE ≥15 kPa) in 3% of those 
tested. This represented a 140% increase in diagnoses 
of cirrhosis within this population, and 72.8% of this 
cohort had normal liver enzymes. Thus, we showed 
feasibility of a risk factor-based approach to identi-
fying and stratifying liver disease across primary and 
secondary care. Furthermore, a formal economic eval-
uation showed this approach is cost-effective.10
In 2016, through discussion with four clinical 
commissioning groups (CCGs) in Nottingham, we 
negotiated an agreed pathway for liver disease stratifi-
cation of patients at risk of liver disease. This included 
patients with a history of harmful alcohol use, risk 
factors for NAFLD or an AST:ALT ratio >0.8 in the 
context of raised liver enzymes. This paper describes 
the Nottingham liver disease stratification pathway, 
a 12-month evaluation of uptake and stratification 
results, and compares the pathway with existing clin-
ical guidance from the British Society of Gastroenter-
ology (BSG).11
MeThodS
Referral process for the pathway
Referral to the pathway (figure 1) is available to all 
patients attending their GP within the four CCG 
catchment areas under the following criteria:
 ► Harmful alcohol use (>50 units/week for men and >35 
units/week for women, or presence of Read codes related 
to alcohol misuse).
 ► An AST:ALT ratio >0.8 in the context of raised liver 
enzymes.
 ► Risk of NAFLD (a fatty liver index (FLI) ≥60,12 and 
(1) presence of obesity, type 2 diabetes or metabolic 
syndrome, or (2) evidence of NAFLD on imaging).
GPs access the pathway by electronic referral through 
a local online system: ‘Integrated Clinical Environ-
ment’ or ‘ICE’. The referrals are then processed by 
the TE clinic team (details below) and an appointment 
is provided directly to the patient. The TE result is 
reported back to the GP with advice on interpretation 
and referral guidelines. Patients who have a TE result 
of <8 kPa are considered below referral threshold 
and are recommended to have a repeat TE in 5 years 
if still indicated. Patients with a TE result between 8 
kPa and 14.9 kPa should be considered for referral to 
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hepatology services (if not, repeat TE in 3 years if indi-
cated). For patients with a TE result ≥15 kPa, referral 
to the local hepatology service is recommended.
Te clinic
The TE clinic is nurse-led at the Queen’s Medical 
Centre, Nottingham University Hospitals NHS Trust. 
The clinic runs from 08:00 to 16:00, 4 days a week 
with ten 30 min patient appointments per day. The 
clinic is staffed by a band 6 nurse with support from 
a band 3 healthcare assistant (both trained to perform 
TE and deliver a brief intervention).
Patients who attend the clinic undergo basic anthro-
pometric measurements of height (cm), weight (kg) and 
blood pressure (mm Hg). Smoking status and alcohol 
intake are documented along with the results of any 
basic blood and liver screen that have been done prior to 
attendance. Patients undergo TE using FibroScan (Echo-
sens, Paris, France), with the result being a median of 
10 readings and validity presented as IQR. They receive 
a brief intervention, regardless of the result. This inter-
vention includes signposting to local alcohol and weight 
management services as appropriate.
Comparison with the BSG guidelines
At present there are no robust guidelines regarding 
patient selection for assessment for significant liver 
disease. The National Institute for Health and 
Care Excellence (NICE) recommends the use of the 
enhanced liver fibrosis (ELF) test in patients with 
evidence of NAFLD, but does not outline any case 
finding strategies. Current BSG guidance recom-
mends assessment for fibrosis using one of the blood-
based parameters in the community (FIB4 or NAFLD 
Fibrosis Score) in patients with suspected NAFLD, but 
only in the context of raised liver enzymes.
In order to examine the potential additional benefit 
of our case finding approach using risk factors over 
a traditional approach, we have compared the strat-
ification results of patients through the Nottingham 
pathway (excluding those referred with harmful 
alcohol intake) with the stratification results should 
the current BSG guidance have been followed, that is, 
assessing only those with raised liver enzymes.
Patient and GP feedback
All patients who attend the TE clinic are requested 
to fill in an anonymous feedback form related to the 
service. This includes questions about the appoint-
ment, the staff and their understanding of the outcome 
of the appointment.
Feedback was also collected from GP practices which 
access the pathway. This was done through a postal 
questionnaire that comprised three questions:
 ► Do the Nottingham liver disease stratification pathway 
guidelines make sense?
 ► Is the Nottingham liver disease stratification pathway 
referral process easy to use?
 ► Has the Nottingham liver disease stratification pathway 
improved patient care?
For each question GPs were asked to rate their 
response from 1 (not at all) to 4 (totally). Two copies 
of the questionnaire were sent to each of the 110 GP 
practices involved.
Analysis
Analyses will evaluate the data collected between 1 
September 2016 and 30 August 2017.
We report on service uptake (clinic attendance rates 
and referral reason), patient characteristics (with/
without elevated TE), liver disease stratification results 
(including comparison with existing guidelines), 
secondary care referral numbers and stakeholder 
feedback.
Descriptive data are presented for clinic attendance, 
referral patterns and waiting times, referral reason 
(defined as harmful alcohol use, AST:ALT ratio >0.8, 
NAFLD or in combination), and stratification of liver 
disease (defined as no significant liver disease TE <8 
kPa, significant liver disease TE 8–14.9 kPa, advanced 
liver disease ≥15 kPa). Categorical data are presented 
as number (percentage). Continuous data are presented 
as mean (SD) for normally distributed data and median 
(range) for non-normal data.
Univariate analysis to compare the characteristics of 
participants with/without elevated TE was undertaken 
using Student’s t-test (normal continuous), Mann-
Whitney U test (non-normal continuous) and χ2 test 
(categorical).
Statistical analysis was performed using STATA V.15.
ReSulTS
Service uptake
In total, 968 patients attended a TE clinic appointment 
through the Nottingham liver disease stratification 
pathway between September 2016 and August 2017. 
The number of patients who attended the clinic increased 
from 24 in month 1, to 129 in month 12 (online supple-
mentary file). The average waiting time for a TE clinic 
appointment was 20 days, and the percentage of used 
appointments to which a patient did not attend ranged 
between 5% and 15% per month.
Patient characteristics
The baseline characteristics and TE results of these 
patients are outlined in table 1.
Of the patients, 941 (97.2%) met one or more of the 
referral criteria. The most common reason for referral 
was AST:ALT ratio >0.8 (357, 36.9%; figure 2). A 
large proportion of patients were referred with either 
NAFLD (223, 23%) or a combination of risk factors 
(267, 27.6%). Two hundred and thirteen (79.8%) of 
those referred for a combination of risk factors were 
for AST:ALT ratio >0.8 combined with either harmful 
alcohol intake or NAFLD. Fewer patients were referred 
with harmful alcohol use as a risk factor alone (94, 
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table 1 Baseline characteristics and TE results of all patients 





Male gender n (%) 470 (49)
Age (years) Mean (SD) 56.3 (13.7)
Body mass index (kg/m2) Mean (SD) 31.2 (6.9)
Current alcohol intake >14 units/
week
n (%) 304 (31.4)
Current smoker n (%) 276 (28.5)
Referral criteria   
  Harmful alcohol use only n (%) 94 (9.7)
  AST:ALT ratio >0.8 only n (%) 357 (36.9)
  NAFLD risk only n (%) 223 (23)
  Combination n (%) 267 (27.6)
  No criteria met n (%) 27 (2.8)
Bilirubin (μmol/L) Mean (SD) 12 (8)
AST (U/L) Median (IQR) 44 (28)
ALT (U/L) Median (IQR) 49 (28)
Albumin (g/L) Mean (SD) 42 (4)
Platelets (×109/L) Mean (SD) 265 (80)
FibroScan result   
  <8.0 kPa n (%) 740 (76.5)
  8.0–14.9 kPa n (%) 165 (17)
  ≥15 kPa n (%) 57 (5.9)
  Technical failure n (%) 6 (0.6)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; NAFLD, 
non-alcoholic fatty liver disease; TE, transient elastography.
Figure 2 (A) Distribution of referral criteria to Nottingham liver 
disease stratification pathway (excluding those who did not meet the 
criteria). (B) Transient elastography results of these patients according 
to the referral criteria. ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; NAFLD, non-alcoholic fatty liver disease.
9.7%). Patients who did not meet the referral criteria 
were more likely to have a normal TE than those who 
had multiple risk factors (92.6% vs 65.5%, p=0.004). 
The average IQR for M and XL probe results was 0.89 
kPa (0.14%) and 1.11 kPa (0.14%), respectively.
Stratification of liver disease
Analysis of TE results that suggest significant liver disease
Liver stiffness was elevated in 222 (22.9%) patients 
(8–14.9 kPa, n=165 (74.3%); ≥15 kPa, n=57 
(25.7%)). Patients with raised liver stiffness were older 
(59.9±13.0 vs 55.3±13.7, p<0.001) and had a higher 
body mass index (33.6±7.4 vs 30.3±6.6, p<0.001) 
than those with a normal liver stiffness (n=740).
Subsequently, 63 patients (38.2%) who had a TE of 
8–14.9 kPa and 45 (78.9%) patients who had a TE of 
≥15 kPa were referred to hepatology services. Of those 
with a TE of 8–14 kPa who were seen in clinic, 4 (2.4%) 
patients received a diagnosis of advanced CLD (Baveno 
VI criteria),13 giving a total of 61 (27.4%) patients.
Analysis of patients with normal liver enzymes: a comparison of 
Nottingham liver disease stratification pathway versus the BSG 
guidelines
Of those referred through the pathway, 96.8% 
(n=937) of patients had a documented ALT result, of 
which 78.5% were raised (ALT >35, n=736). There 
were, however, a significant proportion of patients 
(21.5%, n=201) who had a normal ALT.
There were 744 patients referred to our pathway 
with either AST:ALT ratio >0.8 or NAFLD. Five 
hundred and fifty patients had a raised ALT, of whom 
FIB4 was available in 504. Through the Nottingham 
liver disease stratification pathway, 142 patients were 
found to have significant liver disease (TE ≥8 kPa), of 
whom 32 patients had advanced liver disease (TE ≥15 
kPa). In contrast, only 87 patients with significant liver 
disease (23 patients with advanced liver disease) would 
have been identified if patients had been assessed only 
in the presence of abnormal liver enzymes. This signi-
fies detection of an additional 55 patients using a risk 
factor approach, representing a relative increase in 
detection of 38.7% and an absolute increase in detec-
tion of 7.4% (55/744) of the total number of patients 
referred (figure 3).
Stakeholder feedback
Out of 813 feedback questionnaires received between 
September 2016 and August 2017, 812 (99.9%) 
patients understood the reason for their appointment 
and 731 (89.9%) knew what would happen during the 
appointment. Of the patients 749 (92.1%) were either 
given a choice of appointment time or did not want/
need a choice, and 781 (96%) found it easy to travel 
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Figure 3 Stratification of patients through the Nottingham liver disease stratification pathway compared with standard stratification using the 
BSG guidelines (numbers in brackets ≥15 kPa). ALT, alanine aminotransferase; BSG, British Society of Gastroenterology; TE, transient elastography.
to the appointment. Overall, 804 (98.9%) of patients 
would recommend the service to family and friends.
Out of a possible 220 GP questionnaires, 41 (18.6%) 
were returned. The average score for whether the 
pathway guidelines made sense was 3.6 out of 4, 
whether the pathway was easy to use was 2.9 out of 4, 
and that it had improved patient care was 3.0 out of 4.
dISCuSSIon
The Nottingham liver disease stratification pathway 
is to our knowledge the first commissioned pathway 
in routine clinical care to incorporate stratification of 
patients who are at risk of disease, even in the absence 
of raised liver enzymes or fatty liver on imaging, 
integrating primary and secondary care and enabling 
GP’s direct access to non-invasive assessment of liver 
fibrosis. This pathway was designed through a series 
of pilot studies and implemented through consultation 
with stakeholders and commissioners, and as such has 
resulted in a sustainable stratification model to suit 
local need which has the ability to diagnose disease 
above and beyond the current guidelines.
The prevalence of significant liver disease identi-
fied within primary care is variable depending on the 
diagnostic approach,14 but with rising levels of obesity, 
diabetes and increasing alcohol consumption the 
number of those at risk is growing. Current strategies 
for the identification of those with disease rely heavily 
on raised liver enzymes as a starting point.11 While the 
risk of disease is broadly higher in this group,7 studies 
show that 40%–74.6% of patients with a normal 
ALT have fibrosis on further assessment,14 meaning 
significant numbers of patients with disease may go 
undetected when stratified using a pathway that has 
raised liver enzymes as its first step. Newer models 
that automate the system of investigating patients with 
potential liver disease (which incorporate risk strati-
fication tools) within primary care aim to improve 
access and efficiency of secondary care services,15 but 
still remain reliant on raised liver enzymes to qualify 
for assessment. The Nottingham liver disease stratifi-
cation pathway starts by targeting risk factors and uses 
non-invasive markers of liver fibrosis to identify more 
disease while remaining cost-effective to the National 
Health Service (NHS).10 The importance of this is 
underlined by the fact that an additional 55 patients 
were found to have significant liver disease (TE ≥8 
kPa) and would not have been diagnosed using estab-
lished national guidelines.
A strength of the pathway is that its development 
through pilots to the final commissioning involved 
GPs, commissioners and other stakeholders. Concep-
tually targeting risk factors, making tools accessible to 
GPs and the incorporation of a brief intervention could 
be adapted to suit different populations. For example, 
the pathway has been tailored to evaluate patients 
within drug and alcohol misuse clinics,patients who 
are at risk of significant disease but may not present 
through primary care.
It is interesting to note that despite the intention 
to focus on risk factors and recognise the limitations 
of reliance on raised liver enzymes as a marker of 
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Significance of this study
What is already known on this topic
 ► With rising levels of obesity, diabetes and increasing 
alcohol intake, the number of those at risk of liver 
disease in the community is growing.
 ► Reliance on raised liver enzymes for detection and 
stratification of patients may miss significant liver 
disease.
 ► Stratification of patients at risk of liver disease is cost-
effective to the National Health Service.
What this study adds
 ► The creation of a clinically commissioned, integrated 
referral pathway between primary and secondary care 
is both feasible and effective.
 ► Through a combination of traditional blood-based 
biomarkers, a risk factor approach and transient 
elastography, this pathway identifies disease above 
the current guidance.
How might it impact on clinical practice in the 
foreseeable future
 ► Different iterations of this integrated pathway 
designed to suit local need and risk factor burden may 
provide a more robust way to identify more disease 
early, enabling lifestyle modification and better 
prognosis for patients.
CLD, 37% of patients are currently being referred 
with a raised AST:ALT ratio in the context of raised 
liver enzymes. Through continued effort to increase 
awareness, further evaluation of the newly established 
pathway and dissemination of our findings, efficiency 
of the pathway and the service can be improved further.
One limiting factor of this pathway is the inclu-
sion of the FLI as a preliminary stratification tool in 
patients at risk of NAFLD. Our pilot data have shown 
that the prevalence of significant fibrosis in an unse-
lected population with diabetes is not insignificant 
(31.5%).16 As such, a number of patients with disease 
may go unassessed. The FLI was included during the 
consultation phase of the pathway development—in 
line with the draft NICE guidelines of the time—and 
its use may be withdrawn as the pathway evolves. A 
further limitation of the evaluation of this pathway is 
that we are unable to assess its impact on GPs’ decision 
making. We do not have the data related to referral 
patterns from GPs and are unable to evaluate factors 
that influence patients’ choice and compliance, partic-
ularly in relation to low numbers of patients referred 
with harmful alcohol intake.
ConCluSIon
The Nottingham liver disease stratification pathway is 
a locally commissioned pathway that has been shown 
to be effective by increasing the detection of significant 
liver disease when compared with an approach based 
on raised liver enzymes. The pathway demonstrates 
that providing GPs access to non-invasive markers to 
detect significant liver disease is feasible and has been 
received positively by both patients and physicians.
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